SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 130 filers reported holding SANGAMO THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.69 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,134 | -58.1% | 1,890,425 | -9.3% | 0.01% | -50.0% |
Q2 2023 | $2,709 | +17.6% | 2,083,633 | +59.1% | 0.02% | +15.8% |
Q1 2023 | $2,304 | +234.4% | 1,309,323 | +496.5% | 0.02% | +90.0% |
Q4 2022 | $689 | -100.0% | 219,519 | -37.8% | 0.01% | -56.5% |
Q3 2022 | $1,728,000 | +33.1% | 352,730 | +12.5% | 0.02% | +43.8% |
Q2 2022 | $1,298,000 | +137.7% | 313,442 | +330.5% | 0.02% | +166.7% |
Q4 2021 | $546,000 | -3.7% | 72,815 | +15.8% | 0.01% | -25.0% |
Q3 2021 | $567,000 | -24.8% | 62,878 | -0.2% | 0.01% | 0.0% |
Q2 2021 | $754,000 | +134.2% | 62,991 | +205.6% | 0.01% | +166.7% |
Q4 2020 | $322,000 | -32.8% | 20,611 | -59.3% | 0.00% | -70.0% |
Q3 2020 | $479,000 | +470.2% | 50,660 | +404.6% | 0.01% | +400.0% |
Q4 2019 | $84,000 | -43.6% | 10,039 | -39.0% | 0.00% | -60.0% |
Q3 2019 | $149,000 | +26.3% | 16,470 | +49.7% | 0.01% | 0.0% |
Q2 2019 | $118,000 | – | 11,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Rokos Capital Management LLP | 6,474,348 | $11,394,852 | 0.84% |
WASATCH ADVISORS LP | 13,642,417 | $24,010,654 | 0.15% |
Avidity Partners Management LP | 2,470,000 | $4,347,200 | 0.14% |
Acrisure Capital Management, LLC | 75,832 | $133,464 | 0.14% |
Golden State Equity Partners | 135,765 | $238,946 | 0.13% |
Long Focus Capital Management, LLC | 1,072,000 | $1,886,720 | 0.11% |
KLK CAPITAL MANAGEMENT LLC | 44,323 | $78,008 | 0.10% |
CAXTON ASSOCIATES LP | 288,218 | $507,264 | 0.08% |
XTX Topco Ltd | 206,334 | $363,148 | 0.08% |
Rhenman & Partners Asset Management AB | 314,157 | $534,067 | 0.06% |